MiRXES Files IPO Prospectus Again, Plans to List in Hong Kong within the Year 2024

MiRXES Files IPO Prospectus Again, Plans to List in Hong Kong within the Year 2024

According to reports, MiRXES Group submitted an IPO prospectus to the Hong Kong Stock Exchange on April 30, 2024, with plans to go public in Hong Kong. This move demonstrates the company's strategic decision-making and expansion intentions in the capital market. Founded in 2014, MiRXES is an RNA technology company based in Singapore, focusing on global early disease detection solutions. MiRXES Group is a pioneer in the field of microRNA detection kits and has obtained multiple regulatory approvals. Their core product, GASTROClearTM, consists of 12 miRNA biomarkers and is used for gastric cancer screening. GASTROClear™ is the core product of MiRXES Group, the world's only molecular diagnostic IVD product approved for gastric cancer screening. It has obtained Class C IVD certification from the Health Sciences Authority of Singapore, CE marking, and breakthrough device designation from the U.S. Food and Drug Administration. In addition, MiRXES Group has developed other early cancer detection candidate products, including LungClear™ for lung cancer screening and early detection, CRC-1 for early detection of colorectal cancer, CADENCE for multi-cancer detection, and PHinder, an miRNA detection kit for early detection of pulmonary hypertension developed in collaboration with Actelion Pharmaceuticals. After leading MiRXES through the challenges of 2020, Dr. Zhou is now looking forward to expanding the company's prospects in various areas, including testing services, diagnostic tools, biomarker discovery tools, and manufacturing services. This is by no means an easy task, but MiRXES is poised for success, largely thanks to the dedication and innovative capabilities of Dr. Zhou and the company's team members.